País: Armenia
Idioma: inglés
Fuente: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)
Delpharm Orleans
N02BE51
paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)
650mg+ 10mg+ 20mg
powder for oral solution with lemon flavour
(10) sachets 15g
OTC
Registered
2020-06-30
Property of GSK Consumer Healthcare SA THERAFLU EXTRA LEMON Powder in Sachets Actives substances Paracetamol 650mg; Pheniramine maleate 20mg; Phenylephrine hydrochloride 10mg SUMMARY OF PRODUCT CHARACTERISTICS Document status: FINAL Release date: 17 Apr 2020 Number of pages: 12 Property of GSK Consumer Healthcare SA TABLE OF CONTENTS 1. NAME OF THE MEDICINAL PRODUCT ......................................................................... 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION .............................................. 3 3. PHARMACEUTICAL FORM .............................................................................................. 3 4. CLINICAL PARTICULARS ................................................................................................. 3 4.1 THERAPEUTIC INDICATIONS ................................................................................................ 3 4.2. POSOLOGY AND METHOD OF ADMINISTRATION ................................................................... 3 4.3. CONTRAINDICATIONS ....................................................................................................... 4 4.4. SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE .................................................... 4 4.5. INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION ......... 5 4.6. PREGNANCY AND LACTATION ............................................................................................. 6 4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES ............................................................ 6 4.8. UNDESIRABLE EFFECTS .......................................................................................................6 4.9. OVERDOSE ....................................................................................................................... 9 5. PHARMACOLOGICAL PROPERTIES .............................................................................. 10 5.1. PHARMACODYNAMIC PROPERTIES ................................................. Leer el documento completo